novo nordisk metsera - Search News

Pfizer, Novo Nordisk and Metsera

Pfizer wins $10 billion bidding war for Metsera as Novo Nordisk exits

NEW YORK/LONDON (Reuters) -U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk.

· 6d · on MSN

Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer

· 2d · on MSN

Novo Nordisk gives up battle for Metsera as Pfizer inks $10B deal

· 14h

Metsera falls after accepting up to $10 billion sweetened buyout offer from Pfizer

Metsera accepted a sweetened offer from Pfizer late on Friday, citing U.S. antitrust risks in Novo's bid that it had previously called superior.

· 14h

Novo Rises After Bowing Out of Metsera Takeover Battle

· 19h

Novo Nordisk shares rise after dropping Metsera bid

PharmExec

Novo Nordisk Not Planning Increased Proposal Offer After Metsera Enters $10 Billion Amended Merger Agreement with Pfizer

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an amended acquisition proposal to Metsera for $62.20 per share, a total value of $7.2 billion. Shortly after receiving the amended proposal, Metsera’s board of directors suggested to stockholders to approved Pfizer’s acquisition. 3

Fierce Biotech

Pfizer beats out Novo with $10B agreement to buy Metsera

After a chaotic and fierce bidding clash that only burst out into public view a little more than a week ago, Pfizer has prevailed in its pursuit of obesity biotech Metsera. | After a chaotic and fierce bidding clash that only burst out into public view a little more than a week ago,

Novo Nordisk: Buy This Bargain

Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more about NVO stock here.

BioSpace

Novo Execs Face Skeptical Analysts Amid Metsera Buyout Drama

Investors got to hear Novo Nordisk’s side of the Metsera bidding war drama for the first time on Wednesday, as the company reported third-quarter earnings. A rough quarter underscored the stakes for the Danish pharma.